Earlier published results have shown an increased 5-day survival in burned mice treated with Triglycylvasopressin. In order to analyze the cause of the increased survival, the distribution of cardiac output was studied in 51 mice divided into three groups. The investigation was performed on the 5th day after burn using a soluble indicator technique (86Rb). The first group consisted of unburned animals. In the second and third groups, a standardized burn of 15% of the body surface was undertaken. The animals in the second group were used as controls and received isotonic saline solution for 5 days. The third group received the saline solution and in addition Triglycylvasopressin, a vasopressin with prolonged effect, 100 wg/kg body weight subcutaneously twice a day in such a way that the total volume of fluid was identical in the different groups. Cardiac output distribution showed an increased fraction to kidney, liver and small bowel and a decreased fraction to carcass in the Triglycylvasopressin-treated animals compared to burned controls.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.